Trial Profile
A Phase II, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of SR57667B in Patients With Mild-to-Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Paliroden (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Sanofi
- 22 Sep 2006 New trial record.